Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,164 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Inflammation Clear all
Completed Phase 1 Interventional

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

NCT05034822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional

Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses

NCT01085929
View directory record Official record
Conditions
Abscess, Cellulitis
Interventions
Incision and Drainage, Ultrasound Guided Aspiration
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

NCT04202679
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 2:21 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 1 Interventional

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

NCT00260702
View directory record Official record
Conditions
Hyper-IgE Syndrome, Job's Syndrome
Interventions
Omalizumab (Xolair)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 76 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

NCT03915496
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-04965842 200 mg, PF-04965842 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Largo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 2:21 PM EDT
Completed No phase listed Observational

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)

NCT01778569
View directory record Official record
Conditions
Metabolic Disease, Cardiovascular Disease, Inflammation, Psoriasis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Recruiting No phase listed Observational

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT07645820
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nevisense electrical impedance spectroscopy
Device
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
12 Years to 89 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Las Vegas, Nevada • Portsmouth, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

NCT00985894
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Online Teledermatology Care, Conventional in Office Care
Other
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis

NCT01706913
View directory record Official record
Conditions
Cellulitis
Interventions
Dermatology consult
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Steroid-reducing Effects of Crisaborole

NCT03832010
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 22, 2026, 2:21 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 22, 2026, 2:21 PM EDT
Enrolling by invitation Not applicable Interventional

Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime

NCT06958003
View directory record Official record
Conditions
Diaper Dermatitis
Interventions
Air Therapy
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
30 Weeks to 1 Year
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Not listed Phase 1 Interventional

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03415282
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% topical ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 22, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

NCT01660217
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
A written Eczema Action Plan (EAP)
Other
Lead sponsor
Dermatology & Aesthetics of Wicker Park
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

NCT03585296
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-502
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Encinitas, California • San Diego, California • Fridley, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 22, 2026, 2:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

NCT05688735
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Isosorbide Diester Moisturizer, Control Moisturizer
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 2:21 PM EDT
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 22, 2026, 2:21 PM EDT